Case studies

All

Oncology

Liver + colon + breast

Irinotecan: liver-dependent efficacy, hepatotoxicity, and selectivity

All

Oncology

Liver + breast cancer

Tamoxifen: liver-dependent efficacy on breast adenocarcinoma

All

Oncology

6 cancer types

4-hydroxytamoxifen: selective efficacy on a 6-tissue co-culture

Fluoselect

All

Oncology

2 cancer types

Trastuzumab: binding selectivity in a 2-tissue co-culture

All

Oncology

Liver + colon + breast

Irinotecan: liver-dependent efficacy, hepatotoxicity, and selectivity

All

Oncology

Liver + breast cancer

Tamoxifen: liver-dependent efficacy on breast adenocarcinoma

All

Oncology

6 cancer types

4-hydroxytamoxifen: selective efficacy on a 6-tissue co-culture

Fluoselect

All

Oncology

2 cancer types

Trastuzumab: binding selectivity in a 2-tissue co-culture

All

Oncology

Liver + colon + breast

Irinotecan: liver-dependent efficacy, hepatotoxicity, and selectivity

All

Oncology

Liver + breast cancer

Tamoxifen: liver-dependent efficacy on breast adenocarcinoma

All

Oncology

6 cancer types

4-hydroxytamoxifen: selective efficacy on a 6-tissue co-culture

Fluoselect

All

Oncology

2 cancer types

Trastuzumab: binding selectivity in a 2-tissue co-culture

All

Oncology

Liver + colon + breast

Irinotecan: liver-dependent efficacy, hepatotoxicity, and selectivity

All

Oncology

Liver + breast cancer

Tamoxifen: liver-dependent efficacy on breast adenocarcinoma

All

Oncology

6 cancer types

4-hydroxytamoxifen: selective efficacy on a 6-tissue co-culture

Fluoselect

All

Oncology

2 cancer types